0001104659-24-035104.txt : 20240315 0001104659-24-035104.hdr.sgml : 20240315 20240315183908 ACCESSION NUMBER: 0001104659-24-035104 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bhatt Padmanabh P. CENTRAL INDEX KEY: 0001539215 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 24756419 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm248954-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-13 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001539215 Bhatt Padmanabh P. C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE ROCKVILLE MD 20850 0 1 0 0 Sr. VP of IP, CSO 1 Common Stock 2024-03-13 4 M 0 26250 23.99 A 34820 D Common Stock 2024-03-13 4 S 0 26250 34.10 D 8570 D Common Stock 2024-03-13 4 M 0 36116 12.98 A 44686 D Common Stock 2024-03-13 4 S 0 36116 33.48 D 8570 D Employee Stock Option (Right to Buy) 12.98 2024-03-13 4 M 0 36116 0 D 2026-03-01 Common Stock 36116 0 D Employee Stock Option (Right to Buy) 23.99 2024-03-13 4 M 0 26250 0 D 2030-02-21 Common Stock 26250 8750 D Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.99 to $34.28. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.74. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The option vested in four equal annual installments beginning on March 1, 2017. The option vested in four equal annual installments beginning on February 21, 2021. /s/ Timothy C. Dec, as attorney-in-fact 2024-03-15